<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 334 - MIMS April 2020 E4</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page333.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../MIMS April 2020 E4.html#p=334">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 334 - MIMS April 2020 E4</div>
        <div id="content-top2">P. 334</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../MIMS April 2020 E4.html#p=334"><img src="../thumb/334.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>Endocrine System - 19.3 / 19.4 / 19.5                                          2020-04 / 297








       sertraline/simvastatin, decr. dos. requirm.with concom.androgens/  Contraindications: Ang.of effort, CV disords.  syst./loc.bact./vir.infects., ac.vir.infects. incl.H.Zoster/ocul.H.simplex,
       anabol.ster./ indinavir, insul.oral hypoglycaem.requirem.poss. incr.   Side effects: Angin.pain, palpit., skelet.musc. cramps.  live vaccine vaccinat. for up to 3 mnths.aft.ther.
       in hypothyroid diabets., propranolol plasma conc. reduc., poss.sev.  Special precautions: Excess.burden on card. musc., card.is-  Side effects: Incr.infects.incl.septicaem., incr.GI bleed./ulcerat.,
       hypertens.& tachycard with concom. ketamine, rifampicin reduc.ser.  chaem., lact.intol  ac.adren.insuff.if withdr. rapid.aft. prolong.ther., adren.cortex hyper-
       conc.of thyr. hormon, poss.hypothyroid.in stable pts.with concom.   Drug interactions: Act.of anticoag.enhanc., stabil.of antidiabet.  activ.poss.lead.to Cushing’s syndr., incr.appet., hyperglycaem., Na &
       ciproflox., TSH conc.poss.incr with chloroq. & proguan., imp.absorpt.  agents upset., eff.enhanc.by phenytoin  water retent., oed., hypertens., electrol.disturbs., hypokalaem.alka-
       with soya-bas. inft. formula, furosemide in high dos.(250 mg) poss.   los.from incr.K-excret., poss.CF, osteoporos., spontan.fract., asept.
       displace levothyroxine from plasma prots.& incr. T4 fract.  THYROGEN, (Sanofi) Genzyme  bone necros., myopathy, nitrog.deplet., incr.infect.suscept., menstr.
                                     Thyrotropin alfa             irregularit., amenorrh., hyperhidros., skin thin., ment./neurolog.dis-
       EUTHYROX, (Biopharma Div) Merck [P/S] &  Indications: Adjunct.diagnost.tool for ser. thyroglobulin (Tg) test.  turbs., IC hypertens., ac. pancreatit., growth retardat.in childr., delay.
       Levothyroxine sod.            with/-out whole body radioiod.imaging undertak.for detect.of thyr.   wound heal., thrombo-embol.complicat.
       Indications: Hypothyroid.     remnants & differentiat.thyr.Ca. in post-thyroidect. pts. maint.on   Special precautions: Infect.S&S poss.mask., incr. antidiab./
       (S3) TABS. A39/21.3/0401, 0402, 0403  THST, adjunct.treatm.for radio-iodine. ablation of thyr.tiss.remnants   antihypertens.requirem., concom. anticoags/salicylat., concom.
       713172-002: 25 µg, 30, R19,28  in pts.who have undergone near-tot./tot.thyroidect.for well-differ-  antimuscar.in myasthen.grav., pass.into breastmilk, elderly, HF,
       713168-002: 50 µg, 30, R26,30  entiat.thyr.Ca.& who do not have evid.of distant metastat.thyr.Ca.  recent MI, hypertens., diab.mellit., epilep., glauc., hypothyroid.,
       713169-002: 100 µg, 30, R37,44  (S4) POWD.FOR.SOL.FOR INJ. 43/21.3/0869  hepat.fail., osteoporos., pept.ulcerat., psychos./sev.affect.disords.,
       Dosage: Indiv.accord.to clinic.respons.& biochem. tests. Admin.as   708633-002: 0,9 mg/ml, Kit contain.2 vials, R14 595,86  ren.impairm., reg. assessm. for hypertens./hypokalaem./glycosur./
       sngl.dos.half an hour bef.breakf.  Dosage: For IMI admin.only.  gastr. discomf./ment.disturbs.dur.longt.ther., poss. K-suppl./diet.Na
       Adults: Init.50-100 µg dly. Adjust at 3-4 wk.interv. by 50 µg till norm.  0,9 mg IM, follow.by 2nd 0,9 mg IM inj.aft.24h.  intake reduc., discont.grad.
       metabol.maint. Dos.of 200-300 µg dly.may be reqd. Pts.with card.  Contra Indications: IV.admin., pts.experienc.prior hypersens.re-  Drug interactions: Concom.barbits./phenytoin/ carbamazepine/
       insuffic: Init.25 µg incr.dly.dos.by 25 µg at 4 wk.interv.  acts. to bovine TSH, safety in pregn./ lactat. & safety/effic.in childr.   primidone/rifampicin reduc.eff., incr.GI bleed./ulcerat.with NSAID’s,
       Cretinism & juven.myxoed:  Admin.largest dos.consist.with   &lt; 18 yrs.& hepat. insuff.pts.not est  poss. hypokalaem. from K-deplet.diuret./amphotericin B/xanthine
       freedom from tox.effs. Norm. pulse rate & absence of diarrh.usef.  Side-effects: GI disturbs., headache, dizzin, paraesthes., fatig., as-  bronchodilat./beta  2 agonists, elev. lev.with OC’s/ritonavir, anticoag.
       clinic.indicat.               then., trans.flu-like sympts., urticar., rash, prurit., flush., resp.S&S,   respons.alter., poss.reduc.salicylat.ser.conc., reduc.antimuscarin. eff.
       Cretin.infts: Init.25 µg dly.with 25 µg increm.every 2-4 wks.until mild   enlargem.of resid.thyroid tiss./metastas.
       tox.sympt.appear.when dos.is slightly reduc. Apply the same for ju-  Special Precautions: Only for admin.by practit. knowledgeab.   ASPELONE, (Aspen Pharmacare: Pharma) Pharmacare
       ven.myxoed. except start dos.childr.old.than 1 yr is 2,5-5 µg/ kg/day.  in managem.of pts. with thyr.Ca., thyr.Ca. pts. with metastat.  [N/P/S in C]
       Elderly/coron.heart dis.& sev./long-exist. hypothyroid:   dis. partic.in confin. spaces (e.g. brain/spin.cord/orbit/soft tiss.of   Prednisolone sod.phosph.equiv.to prednisolone
       Init.12,5 µg/day incr.slow.at lengthy interv.of 12,5 µg/day fortnightly.  neck) may be subj.to loc.oed./foc.haemorrh.at site of metastas. &   Indications: Steroid respons.inflammat.condits.
       Contraindications: Untreat.adren.insuffic., untreat. pituit.insuf-  considerat.of.corticoster.pretreatm. recomm. in pts.in whom loc.  (S4) SYRUP, 41/21.5.1/0189. 15 mg/5 ml.
       fic., untreat.thyrotoxicos., ac. MI, ac.myocardit., ac.pancardit.,   tumour expans.may comprom. vital anatom.struct.prior to admin.,   714552-001: 50 ml, R112,57
       untreat. hyperthyroid., heredit.galact.intol./Lapp lact.defic./ gluc.-  false negat.results may occ.& if high index of suspic.for metastat.  Dosage: Indiv.accord.to dis., its sever.& pt. respons. Usual dos.
       galact.malabsorpt.            dis.persists confirmat.withdraw. diagnost. or post-ther.WBS & Tg   range: 3-60 mg dly.in div.dos.
       Side effects: Undesir.eff.gen.assoc.with excess. dos /if dos.incr.  test.should be consid., radioiod.retent.at time of radioiod. diagnost.   Total dly.dos.may be admin.as sngl.dos.early morn./ as double dos.
       too quickly at start of treatm.& usually disappear aft.dos.reduct./  imaging poss.reduc.in pts.treat.with Thyrogen & should be consid.  on alt.days. Some pts.may require high.init.dos. where low.dos.may
       temporar.treatm. withdr. Sympts report.incl.heat intol., sweat.,   when select.activit.of radioiod.for use in radioiod.imaging., eval.be-  be suffic. in less sev. situat. Adjust.init.dos.unt.satisfact. respons.ob-
       flush., fev., weight loss, nervousn., excitability, insomn., headache,   nef. vs. risk for high risk elderly with func.thyr.tumours &/ pts.with   serv.& maint.thereaft. Infts.& childr: Accord.to ratios indic.by age or
       trem., cephalalg., pseudotumor cerebri, tachycard., palpitat., card.  heart dis.(e.g. valvul.heart dis., cardiomyopathy, cor.artery dis. &   body mass also consid. guidel.used when prescib.adult dos. Discont.
       arrhythm., ang. pain, diarrh., vomit., hyperhidros., musc.weakn.,   prior/curr. tachydysrhythm.).  grad.if spontan.remiss.occurs in chron. condit.
       cramps, menstr.irregularit., allerg.react.                 Contraindications: Pregn., lactat., osteoporos., oesophagit., gas-
       Special precautions: Excl./treat.coron.insuffic./ ang. pect./ar-  trit., pept.ulc., ac.psychos., sev. psychoneuros., syst.fung.infects.,
       terioscleros./hypertens./pituit.insuffic. /adren.insuffic.& thyroid   uncontr. system./loc.bact.or vir.infects., act./quiesc.TB, ac.vir.infects.
       autonomy, avoid drug-induc. hyperthyroid.in coron.fail./card.insuf- 19.4   Parathyroid and calcitonin  such as herpes zoster/ocul.herpes simpl.
       fic.& tachycard. arrhythm.theref.check thyroid hormon. paramet.   Side effects: Ac.adren.insuffic.with rapid withdr. aft. prolong.ther.,
       reg., determ.cause of second. hypothyroid. bef.init.replacem.ther.,   FORTEO, Eli Lilly [P/S]  incr.infect.suscept, may mask signs of infect., delay.wound heal.,
       post-menopaus. women with incr.osteoporos.risk, corticoster. ther.  Teriparatide (rDNA origin)  water & sod. retent. with oed./hypertens./electrol.bal.disturbs. &
       advis.bef.init.ther.in panhypopituitarism/ other causes predispos.to   Indications: Est.osteoporos.with/without vertebr.fract.in postmen-  hypokalaem.alkalos., CF, Cushing’s syndr., osteoporos., spontan.
       adren. insuffic., myocard.insuffic./ECG evid.of MI, monit. bld.gluc of   opaus.women & prim. osteoporos in men, osteoporos.assoc.with   fract., myopathy, nitrog. deplet., hyperglycaem., incr.appet., men-
       diabet., anticoag.ther., admin. colestyramine & colestipol 4-5 hrs.  sustain. syst.glucocortic.ther.in women & men at incr.risk of fract.  str. irregularit., amenorrh., benign IC hypertens., thrombo-embol.
       bef., thyroid hormon. to be given consist.dur.pregn.& breast feed.   (S4) SOL FOR INJ, 36/21.4/0334.  complicat., avascul.bone necros., musc. weakn., skin thinn., ocul.
       but thyroid funct.to be monit.  250 µg/ml (20 µg/dos.)     chang.incl.glauc. & cataract developm., growth retardat.in childr.,
       Drug interactions: Effs.of antidiabet.drugs poss. reduc., effs.of an-  702800-001: 1x2,4 ml prefill.cart.del.dev., R4 566,98  ac. pancreatit., hyperhidros.
       ticoag.enhanc., absorpt.inhibit./ reduc.by colestyramine/colestipol/  Dosage: Recom.dos: 20 µg once dly.by SC inj.in thigh/ abdom. Ad-  Special precautions: Poss. reduc.eff.of antimuscarin. in mysthen.
       Al & Fe-contain. drugs / Ca carbon.& soy contain cmpds., meds.   min.concom.Ca 1000 mg & Vit.D 400 - 1 200 IU/day  grav., discont.grad., diab. mellit., elderly, HF, rec.MI, hypertens.,
       with high affinit.for plasma prot.may result in elev. free-thyrox(T4)   Contraindications: Hypercalcaem., metabol. bone dis. other than   epileps., glauc., hypothyroid., osteoporos., pept.ulcerat., psychos.,
       fract., propylthiouracil/glucocortic./ beta-sympatholyt./amiodarone   prim.osteoporos.(incl. hyperparathyroid.& Paget’s dis), skelet.malign/   sev.affect.disords., ren.mpairm., do not immun. with live vaccine
       & Iodine-contain. contrast media inhibit.periph.convers.of T4 to T3,   bone metastases, excl.pts with prior extern. beam/implant radiat.  vaccinat. for up to 3 mnths.aft.high dos.steroid ther., cont.sorbit /
       sertraline/ chloroquine & proguanil decr.effic.& incr. TSH lev., hepat.  ther.involv.skelet., safety in pregn.& lactat.not est., childr.& young   glycerol & sweetn.
       clear.incr.by barbitur.& other drugs induc.hepat.enzymes, women on   adults with open epiphyses.  Drug interactions: Barbitur./carbamazepine/ phenytoin/ primidone
       oestrog. contain OC’s /HRT may have incr.needs.  Side effects: Leg cramps, naus., hyperuricaem., allerg.events, trans.  & rifampicin reduc.effs., OC’s/ ritonavir elev.plasma lev., hypokalaem.
       See also MDR page 496.        orthostat.hypotens., musc.& back spasms.  poss. with K-deplet. diuret./amphotericin B & xanthines, poss. incr.
                                                                  GI bleed./ulcerat.with NSAIDs, alt. respons. to anticoag., antidiab.&
       NEO-MERCAZOLE, (Aspen Pharmacare: Pharma)    Special precautions: Excl.hypercalcaem.bef. init. ther., monit.  antihypertens. agent requirem.poss.incr., reduc.salicylate ser. conc.
                                     ser.Ca (obt.bld.samples 16 hrs. aft.last dos.), poss.exacerbat.of
       Pharmacare [P/S]
       Carbimazole.                  act./rec. urolithiasis.      BE-TABS PREDNISONE, Ranbaxy [N/P/S in C]
       Indications: Hyperthyroid., thyrotoxic., prep.for thyroidect.  Prednisone.
       (S3) TABS. G3021.                                          Indications: Rheumat.arthrit., nephrot.syndr., collag. dis., fulminat.
       746398-018: 5 mg, 100, R590,65  19.5  Corticosteroids      SLE, allerg.condits., bronch. asthma, ac.skin dis., chron.ulcerat.colit.,
       Dosage: 10-60 mg dly in div.dos. Reduc.grad.to smallest optim.dose.  thrombo-cytopen., organ.transplantat.
       Contraindications: Tracheal obstruct., ser.pre-exist.haematolog,      (See also 12.9, 14.4, 14.4.1, 15.2)   (S4) TABS. G3004.
       condits., sev.hepat.insuffic., hypersens.to other thiourea antithy-  788783-009: 5 mg, 1 000, R223,48
       roid agents.                  ADCO-PREDNISOLONE, AI Pharm Ltd [N/P/S in C]  Dosage: Indiv.accord.to sev.& respons.
       Side effects: Rash, headache, GI disturb., agranulocyt., alo-  Prednisolone.  Rheumat.arthrit: Init. 10 mg incr.slow.to desir. control.
       pec., hepatit.                Indications: Sympt.relief in steroid respons. inflammat.condits.  Nephrot.syndr: 60 mg dly in div.dos. (2 mg/kg oed.free bm in
       Special precautions: Pregn., lact.intol.  (S4) SYRUP. 38/21.5.1/0125. 15 mg/5 ml  childr.) x3-4 wks.
                                     716381-001: 50 ml, R43,04
                                                                  Collag.dis: 1 mg/kg dly.until remiss.induc.
       TERTROXIN, (Aspen Pharmacare: Pharma) Pharmacare [P/S]  Dosage: Indiv.accord.to dis., its sever.& pt. respons. Usual dos.  Fulminat.SLE: 1 mg/kg dly.incr.in 20 mg increm. dly.until desir.re-
       Liothyronine sod.             range: Adults: 5-60 mg dly.in div. dos. Max.dos: 1 -2 mg/kg. May   spons., then reduc.by 5 mg/wk.till further reducts.elucidate sympts.
       Indications: Myxoed.coma, sev.chron.thyroid defic., hypothyroid   be giv.dly.as sngl.dos.aft. breakf.or as doubl.dos.on altern.days.   Bronch.asthma: Status asthmatic: IV cortisol to control attack
       states in thyrotoxicos.treatm., thyrotoxicos.therap.with carbimazole.  Paed.dos: Usual.0,5-2 mg/kg bm or 15-60 mg/sq. meter body   then 10 mg x4-5 days.
       (S3) TABS. G3082.             surf.area in 3 div.dos.      Sev.chron.bronch.asthma: 5-10 mg dly in div. dos.in combinat.
       769983-006: 20 µg, 50, R124,19  Contraindications: Pregn.& lactat., osteoporos., oesophagit., gas-  with usual medicat.
       769983-007: 20 µg, 100, R248,38  trit., pept.ulcerat., ac.psychos., sev.psychoneuros., act./quiesc.TB ex-  Skin dis: 40-120 mg/day.
       Dosage: 5-100 µg dly.in div.dos.  cept rarely as adjunct. to anti-TB treatm., syst.fung.infects., uncontr.   Chron.ulcerat.colit: 60-120 mg/day.
                            S4 JARDIANCE ®  10 mg: Each film-coated tablet contains empagliflozin 10 mg. Reg. No. 48/21.2/1380. S4 JARDIANCE ®  25 mg: Each film-coated tablet contains empagliflozin 25 mg.
                            Reg. No. 48/21.2/0411. For full prescribing information refer to the professional information approved by the Regulatory Authority. Applicant details: Ingelheim Pharmaceuticals (Pty) Ltd,
                            407 Pine Ave, Randburg. Tel: +27 (011) 348-2400. Cpy. Reg. No. 1966/008618/07. BI Ref. No. PC-ZA-100408. Expiry date: August 2021.</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page333.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page329.html">329</a>&nbsp;&nbsp;&nbsp;<a href="page330.html">330</a>&nbsp;&nbsp;&nbsp;<a href="page331.html">331</a>&nbsp;&nbsp;&nbsp;<a href="page332.html">332</a>&nbsp;&nbsp;&nbsp;<a href="page333.html">333</a>&nbsp;&nbsp;&nbsp;<a href="page334.html">334</a>&nbsp;&nbsp;&nbsp;<a href="page335.html">335</a>&nbsp;&nbsp;&nbsp;<a href="page336.html">336</a>&nbsp;&nbsp;&nbsp;<a href="page337.html">337</a>&nbsp;&nbsp;&nbsp;<a href="page338.html">338</a>&nbsp;&nbsp;&nbsp;<a href="page339.html">339</a>
             </td>
             <td width="35%"><a href="page335.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page335.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
